FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma
May 28
2019
The Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
